SNAP-94847

SNAP-94847
Identifiers
	IUPAC name N-(3-[1-([4-(3,4-difluorophenoxy)phenyl]methyl)(4-piperidyl)]-4-methylphenyl)-2-methylpropanamide;
ChemSpider	10795817;
ECHA InfoCard	100.230.605
Chemical and physical data
Formula	C29H32F2N2O2
Molar mass	478.584 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(cc1F)Oc(cc4)ccc4CN(CC3)CCC3c2cc(NC(=O)C(C)C)ccc2C;
	InChI InChI=1S/C29H32F2N2O2/c1-19(2)29(34)32-23-7-4-20(3)26(16-23)22-12-14-33(15-13-22)18-21-5-8-24(9-6-21)35-25-10-11-27(30)28(31)17-25/h4-11,16-17,19,22H,12-15,18H2,1-3H3,(H,32,34); Key:VMLZFUVIKCGATC-UHFFFAOYSA-N;
	(verify)

SNAP-94847 is a drug used in scientific research, which is a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH₁. In animal studies it has been shown to produce both anxiolytic and antidepressant effects,^[1]^[2] and also reduces food consumption suggesting a possible anorectic effect.^[3]

References[edit]

^ David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XI, Dong D, Marzabadi MR, Gerald CP, Hen R (April 2007). "Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis". The Journal of Pharmacology and Experimental Therapeutics. 321 (1): 237–48. doi:10.1124/jpet.106.109678. PMID 17237257. S2CID 717425.
^ Smith DG, Hegde LG, Wolinsky TD, Miller S, Papp M, Ping X, Edwards T, Gerald CP, Craig DA (February 2009). "The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents". Behavioural Brain Research. 197 (2): 284–91. doi:10.1016/j.bbr.2008.08.026. PMID 18793675. S2CID 205878561.
^ Nair SG, Adams-Deutsch T, Pickens CL, Smith DG, Shaham Y (July 2009). "Effects of the MCH1 receptor antagonist SNAP 94847 on high-fat food-reinforced operant responding and reinstatement of food seeking in rats". Psychopharmacology. 205 (1): 129–40. doi:10.1007/s00213-009-1523-6. PMC 3143407. PMID 19340414.

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

[pmid17237257-1] David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XI, Dong D, Marzabadi MR, Gerald CP, Hen R (April 2007). "Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis". The Journal of Pharmacology and Experimental Therapeutics. 321 (1): 237–48. doi:10.1124/jpet.106.109678. PMID 17237257. S2CID 717425.

[pmid18793675-2] Smith DG, Hegde LG, Wolinsky TD, Miller S, Papp M, Ping X, Edwards T, Gerald CP, Craig DA (February 2009). "The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents". Behavioural Brain Research. 197 (2): 284–91. doi:10.1016/j.bbr.2008.08.026. PMID 18793675. S2CID 205878561.

[pmid19340414-3] Nair SG, Adams-Deutsch T, Pickens CL, Smith DG, Shaham Y (July 2009). "Effects of the MCH1 receptor antagonist SNAP 94847 on high-fat food-reinforced operant responding and reinstatement of food seeking in rats". Psychopharmacology. 205 (1): 129–40. doi:10.1007/s00213-009-1523-6. PMC 3143407. PMID 19340414.

[1]

[2]

[3]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III